Wall St Engine
@wallstengine
Fast, accurate, consistent stock market news, earnings highlights & more. By Brillinsight. Not financial advice.
加入 March 2022
977 正在關注 199.4K 粉絲
Kodiak Sciences $KOD +150%
Its eye-disease drugs Zenkuda and tabirafusp-ted met the primary endpoints in the pivotal Phase 3 DAYBREAK trial in wet AMD.
Kodiak plans to file Zenkuda for approval in Q4, backed by five positive Phase 3 studies.
顯示更多
